Some studies have indicated that the expression of PD-L1 within the tumor microenvironment has predictive value for the response to PD-1 inhibitors in melanoma (47–49), NSCLC (50, 51), and bladder cancer (52). This evidence concerns the gene CD274 and neoplasm.